Product Description
Mechanisms of Action: AChR Stimulant
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: China Resources Shuanghe Limin Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Infarction, Middle Cerebral Artery|Amphetamine-Related Disorders|Methamphetamine Dependence|Vertigo|Ischemic Stroke|Kidney Diseases|Cocaine-Related Disorders|Heart Failure, Chronic|Opioid-Related Disorders|Dizziness|Binge Drinking|Alcoholism|Heart Block|Peripheral Nervous System Diseases
Phase 3: Myalgia|Postpoliomyelitis Syndrome|Muscle Weakness|Tardive Dyskinesia|Dyskinesias
Phase 1: Cocaine-Related Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DPN | P4 |
Not yet recruiting |
Peripheral Nervous System Diseases |
2025-06-01 |
|
| N23PIR | P4 |
Not yet recruiting |
Binge Drinking|Vertigo|Opioid-Related Disorders|Cocaine-Related Disorders|Heart Failure, Chronic|Amphetamine-Related Disorders|Methamphetamine Dependence|Kidney Diseases|Alcoholism|Heart Block |
2023-09-30 |
|
| CTR20230523 | N/A |
Completed |
Cerebrovascular Trauma |
2023-04-19 |
|
| ChiCTR2000040466 | N/A |
Recruiting |
Unknown |
2022-12-31 |